# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Abivax shares jump as obefazimod meets key Phase 3 trial endpoints in ulcerative colitis with strong remission rates and a favo...
The Company Intends to Request a Review of the Delisting DeterminationCRANBURY, N.J., May 7, 2025 /PRNewswire/ -- Palatin Techn...
Funding Supports Advancement of Obesity Program and Strategic Business Development InitiativesAdvancement of novel next-generat...
$11.5 Million Upfront with up to an Additional $11.5 Million Upon the Cash Exercise of the Milestone Related Warrants